High preoperative bilirubin values protect against reperfusion injury after live donor liver transplantation

Transplant International

Volumn 28, Issue 11, 2015, Pages 1317-1325

  Spetzler, Vinzent N ^a   Goldaracena, Nicolas ^a   Kaths, Johann M ^a   Marquez, Max ^a   Selzner, Nazia ^a   Cattral, Mark S ^a   Greig, Paul D ^a   Lilly, Les ^a   McGilvray, Ian D ^a   Levy, Gary A ^a   Ghanekar, Anand ^a   Renner, Eberhard L ^a   Grant, David R ^a   Selzner, Markus ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

bilirubin; biliverdin; heme oxygenase 1; ischemia reperfusion injury; live donor liver transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; HEME OXYGENASE 1; HMOX1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; LENGTH OF STAY; LIVER FUNCTION; LIVER INJURY; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REPERFUSION INJURY; ADOLESCENT; ADVERSE EFFECTS; AGED; BLOOD; BODY MASS; CHOLANGITIS, SCLEROSING; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BILIRUBIN; BODY MASS INDEX; CHOLANGITIS, SCLEROSING; FEMALE; GRAFT SURVIVAL; HEME OXYGENASE-1; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; REPERFUSION INJURY; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937723397     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12634     Document Type: Article

References (32)

1. Fondevila C, Busuttil RW, Kupiec-Weglinski JW,. Hepatic ischemia/reperfusion injury-a fresh look. Exp Mol Pathol 2003; 74: 86.
2. Chen XB, Xu MQ,. Primary graft dysfunction after liver transplantation. Hepatobiliary Pancreat Dis Int 2014; 13: 125.
3. Mourad MM, Algarni A, Liossis C, Bramhall SR,. Aetiology and risk factors of ischaemic cholangiopathy after liver transplantation. World J Gastroenterol 2014; 20: 6159.
4. Cursio R, Gugenheim J,. Ischemia-reperfusion injury and ischemic-type biliary lesions following liver transplantation. J Transplant 2012; 2012: 164329.
5. Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW,. Ischaemia-reperfusion injury in liver transplantation-from bench to bedside. Nat Rev Gastroenterol Hepatol 2013; 10: 79.
6. Origassa CS, Camara NO,. Cytoprotective role of heme oxygenase-1 and heme degradation derived end products in liver injury. World J Hepatol 2013; 5: 541.
7. Richards JA, Wigmore SJ, Devey LR,. Heme oxygenase system in hepatic ischemia-reperfusion injury. World J Gastroenterol 2010; 16: 6068.
8. Sass G, Barikbin R, Tiegs G,. The multiple functions of heme oxygenase-1 in the liver. Z Gastroenterol 2012; 50: 34.
9. Wang CF, Wang ZY, Li JY,. Dual protective role of HO-1 in transplanted liver grafts: a review of experimental and clinical studies. World J Gastroenterol 2011; 17: 3101.
10. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN,. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043.
11. Llesuy SF, Tomaro ML,. Heme oxygenase and oxidative stress. Evidence of involvement of bilirubin as physiological protector against oxidative damage. Biochim Biophys Acta 1994; 1223: 9.
12. Stocker R, Peterhans E,. Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Radic Res Commun 1989; 6: 57.
13. Baranano DE, Rao M, Ferris CD, Snyder SH,. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 2002; 99: 16093.
14. Kamath PS, Wiesner RH, Malinchoc M, et al,. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464.
15. Manzinate F, McDaid J, Devey L, Gunson B, Wigmore SJ,. Pretransplant bilirubin concentration does not correlate with early reperfusion injury following liver transplantation. Transplantation 2007; 83: 103.
16. The Medical Council of Canada. Clinical Laboratory Tests-Normal Values. Objectives for the Qualifying Examination 2014 [cited 2014 July 15, 2014]; Available from: http://apps.mcc.ca/Objectives-Online/objectives.pl?lang=english&loc=values.
17. Cattral MS, Molinari M, Vollmer CM Jr, et al,. Living-donor right hepatectomy with or without inclusion of middle hepatic vein: comparison of morbidity and outcome in 56 patients. Am J Transplant 2004; 4: 751.
18. Adcock L, Macleod C, Dubay D, et al,. Adult living liver donors have excellent long-term medical outcomes: the University of Toronto liver transplant experience. Am J Transplant 2010; 10: 364.
19. Reichman TW, Katchman H, Tanaka T, et al,. Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes. Transpl Int 2013; 26: 780.
20. Rosen HR, Martin P, Goss J, et al,. Significance of early aminotransferase elevation after liver transplantation. Transplantation 1998; 65: 68.
21. Clavien PA, Barkun J, de Oliveira ML, et al,. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187.
22. Busuttil RW, Tanaka K,. The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651.
23. Ollinger R, Wang H, Yamashita K, et al,. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal 2007; 9: 2175.
24. Kato Y, Shimazu M, Kondo M, et al,. Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning. Hepatology 2003; 38: 364.
25. Fondevila C, Shen XD, Tsuchiyashi S, et al,. Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology 2004; 40: 1333.
26. Lee JP, Kim do H, Yang SH, et al,. Serum bilirubin affects graft outcomes through UDP-glucuronosyltransferase sequence variation in kidney transplantation. PLoS One 2014; 9: e93633.
27. Weismuller TJ, Fikatas P, Schmidt J, et al,. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany-limitations of the 'sickest first'-concept. Transpl Int 2011; 24: 91.
28. Klein KB, Stafinski TD, Menon D,. Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature. PLoS ONE 2013; 8: e80661.
29. Hoffmann K, Hinz U, Hillebrand N, et al,. The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases. Langenbecks Arch Surg 2014; 399: 1001.
30. Onaca NN, Levy MF, Netto GJ, et al,. Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant 2003; 3: 626.
31. Onaca NN, Levy MF, Sanchez EQ, et al,. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003; 9: 117.
32. Selzner M, Kashfi A, Cattral MS, et al,. Live donor liver transplantation in high MELD score recipients. Ann Surg 2010; 251: 153.